AI News - September 30, 2026

Today's Generative AI News📅 September 30, 2026🎨 Infographics by News ItemFor all 8 items covered today, I have included an ...

Imbalance charges to have a 300 yen cap starting October 1st — 'Price tags' for supply-demand tightness rise, and the OCCTO to publish a new signal: 'Wide-area S…

OverviewOn September 29, 2026, the Organization for Cross-regional Coordination of Transmission Operators, Japan (hereinafter ...
MarketScreener

Roche : fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability 1; Fenebrutini ...
MarketScreener

Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability Fenebrutinib became the first ...